Pfizer Initiates Phase III Trial for Sunitinib Malate in Metastatic Colorectal Cancer

Pfizer announced the initiation of a Phase III clinical trial to evaluate the safety and efficacy of sunitinib malate in combination with a standard chemotherapy regimen in patients with metastatic colorectal cancer (mCRC).

A current multinational Phase III study is enrolling in Europe, Canada, Asia and South America and will include more than 700 patients to evaluate the safety and efficacy of sunitinib malate combined with Folfiri, a standard chemotherapy regimen for mCRC, which is comprised of fluorouracil (5-FU), folinic acid (leucovorin) and irinotecan, compared with Folfiri plus placebo in the first-line treatment, Pfizer said.

Sunitinib malate is a multikinase inhibitor that works by preventing cell multiplication, according to the company.